Tandem Diabetes Care prices upsized IPO at $15, at high end of the range
Tandem Diabetes Care, which manufactures a next-generation insulin pump for diabetics, raised $120 million by offering 8.0 million shares at $15, the high end of the range of $13 to $15. The company had originally planned to offer 7.1 million shares. Tandem Diabetes Care plans to list on the NASDAQ under the symbol TNDM. Tandem Diabetes Care initially filed confidentially on 8/12/2013. BofA Merrill Lynch and Piper Jaffray acted as lead managers on the deal.